Your session is about to expire
← Back to Search
Nonsteroidal Anti-inflammatory Drug
Aspirin for Cardiovascular Disease (CAPE Trial)
Phase 4
Waitlist Available
Led By Kathryn T Hall, PhD
Research Sponsored by Brigham and Women's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
healthy, 18-40 years
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at end of treatment 10-14 days the platelets will be activated on the same day as blood collection.
Awards & highlights
CAPE Trial Summary
This trial will examine the role of genetic variation in COMT on platelet function in a blinded, randomized, placebo controlled clinical trial of daily placebo or Aspirin (81mg) for 10 ± 3 days. Platelet function will be assessed with platelet aggregometry and by fluorescence-activated cell sorting (FACS) of platelet adhesion molecules P-selectin and GPIIb/IIIa in platelets activated with arachidonic acid, thrombin, collagen, epinephrine and ADP.
CAPE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCAPE Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at end of treatment 10-14 days the platelets will be activated on the same day as blood collection.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at end of treatment 10-14 days the platelets will be activated on the same day as blood collection.
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
platelet aggregation
Secondary outcome measures
% expression of P-selectin on resting and activated platelets
CAPE Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: AspirinActive Control1 Intervention
Aspirin (81mg) will be taken orally daily for 10-14 days.
Group II: PlaceboPlacebo Group1 Intervention
Placebo pills that are visually identical to the Aspirin pills will be taken orally, daily for 10-14 days
Find a Location
Who is running the clinical trial?
Brigham and Women's HospitalLead Sponsor
1,612 Previous Clinical Trials
11,470,530 Total Patients Enrolled
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,836 Previous Clinical Trials
47,851,003 Total Patients Enrolled
Kathryn T Hall, PhDPrincipal InvestigatorBrigham and Women's Hospital
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger